Prognosis following the initiation of various immune checkpoint inhibitor therapies in TTF-1-negative non-small cell lung cancer.
The hypothesis that CTLA-4 antibody-containing regimens may be effective for patients with TTF-1-negative non-squamous NSCLC is suggested, although the present study failed to identify the immune checkpoint inhibitor therapy associated with improved survival.